Last reviewed · How we verify
Anti-coagulation therapy
Anti-coagulation therapy is a Small molecule drug developed by Boston Scientific Corporation. It is currently in Phase 3 development.
Anti-coagulation therapy involves the use of exogenous proteins, specifically targeting coagulation factor VIII, to prevent or treat conditions such as hemophilia A. This therapy is currently being studied in clinical trials, including a qualitative study on home monitoring of hemostasis in anticoagulant treatment and hemophilia A (NCT06702579).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Anti-coagulation therapy |
|---|---|
| Sponsor | Boston Scientific Corporation |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury (NA)
- WATCHMAN FLX Pro European Registry (NA)
- Acupuncture for Preventing Atrial Arrhythmia Recurrence After Ablation (NA)
- Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation (NA)
- A Trial of Pharmacist Management of Oral Anticoagulation THerapy in the communitY for AF (PHASE4)
- A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-coagulation therapy CI brief — competitive landscape report
- Anti-coagulation therapy updates RSS · CI watch RSS
- Boston Scientific Corporation portfolio CI
Frequently asked questions about Anti-coagulation therapy
What is Anti-coagulation therapy?
Who makes Anti-coagulation therapy?
What development phase is Anti-coagulation therapy in?
Related
- Manufacturer: Boston Scientific Corporation — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing